Stellaromics, a pioneer in 3D spatial biology spun out of the laboratories of Karl Deisseroth (Stanford University) and Xiao Wang (MIT and Broad Institute), announced the completion of a Series B funding round for $80Mn.
Read also – Nirmata Raises $9.6 Mn to Expand AI-Driven Cloud-Native Policy-as-Code Solutions
The round, led by Catalyst4 with participation from Stanford University Ventures, will support the development and commercialization of Pyxa, Stellaromics’ groundbreaking 3D spatial biology platform.
Read also – ACT-ion Raises $7.5 mn in Pre-Series A Funding
Unveiled today, the Pyxa platform enables researchers to visualize and analyze the spatial organization of cells and molecules within thick tissue samples at an unprecedented resolution. These breakthroughs, based on the company’s STARmap and RIBOmap technologies, greatly expand upon applications of traditional 2D methods by offering a true 3D perspective, providing researchers with a deeper understanding of tissue organization, cellular interactions, and disease mechanisms.
“We are excited to introduce Pyxa, a 3D profiling technology platform that will redefine the boundaries of spatial biology,” said Todd Dickinson, CEO of Stellaromics. “By providing a true three-dimensional multi-omic representation of biological systems, Pyxa will empower researchers to make breakthrough discoveries that deepen our understanding of human biology and accelerate the development of new diagnostics and therapeutics.”
With its ability to analyze both thin and thick tissue sections with sub-cellular resolution, Pyxa overcomes longstanding limitations in spatial biology, allowing researchers to explore cellular organization in ways never before possible. This advancement is already proving valuable across neuroscience, oncology, and immunology, where understanding tissue architecture at this level can unlock critical insights into disease mechanisms.
“As a scientific co-founder, it’s incredibly gratifying to see this technology come to fruition and empower researchers to explore the intricacies of biology in 3D,” said Xiao Wang, Core Member at the Broad Institute.
About Stellaromics
Stellaromics is a privately held company dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company’s mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health. Stellaromics is headquartered in Boston, Massachusetts, USA.
